Security key
H17182108
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 47,858,309
- Total 13F value
- $4,002,814,216
- Share change
- +8,562,033
- Put/Call ratio
- 105%
- SEC-reported price per share
- $83.64
- Number of holders
- 300
- Value change
- +$723,322,979
- Number of buys
- 151
- Number of sells
- 112
- Shares outstanding
- 96,669,746
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2020
Institutions
300
Top holders
10
CRSP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2020
Previous quarter: Q2 2020
CRISPR Therapeutics AG SEC filings
CRISPR Therapeutics AG company facts
Broader feeds
Reporting periods
Holder history for CUSIP H17182108
Recent filing periods:
Ownership snapshot
Top reported holders of CRSP - CRISPR Therapeutics AG - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARK Investment Management...
Disclosed value leader
ARK Investment Management...
Comparable rows
15/15
Latest evidence
30 Jun 2020
13F
Lead comparable stake: 6.7%
Showing 1-6 of 15 holder rows.
Quick read
ARK Investment Management LLC leads the comparable SEC ownership view at 6.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARK Investment Management LLC's linked filing trail.
Comparable ownership
Top 5
ARK Investment Management LLC
6.7%
Versant Venture Management, LLC
4.3%
Amova Asset Management Americas, ...
3.8%
NEA Management Company, LLC
2.2%
PRICE T ROWE ASSOCIATES INC /MD/
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARK Investment Management LLC |
13F
Company
|
6.7%
|
$476,454,000
6,483,251 shares
|
— | 30 Jun 2020 |
| Versant Venture Management, LLC |
13F
Company
|
4.3%
|
$307,413,373
4,183,064 shares
|
— | 30 Jun 2020 |
| Amova Asset Management Americas, Inc. |
13F
Company
|
3.8%
|
$269,118,000
3,711,970 shares
|
— | 30 Jun 2020 |
| NEA Management Company, LLC |
13F
Company
|
2.2%
|
$153,644,000
2,090,678 shares
|
— | 30 Jun 2020 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
1.4%
|
$101,073,000
1,375,327 shares
|
— | 30 Jun 2020 |
| FEDERATED HERMES, INC. |
13F
Company
|
1.1%
|
$79,222,000
1,078,000 shares
|
— | 30 Jun 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
300
Shares
47,858,309
Rows available
300
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2020 vs Q2 2020 Across Filers
Q2 2020 holders
263
Q3 2020 holders
300
Holder diff
37
| Investor | Q2 2020 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q2 2020 value | Q3 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend